Article
Immunology
Hua Li, Xiaofan Li, Yiling Chen, Duihong Li, Xianling Chen, Zhijuan Zhu, Yiting Wang, Jiafu Huang, Ping Chen, Yuanzhong Chen, Nainong Li
Summary: The study showed that sequential Haplo-cord HSCT with ATG/PTCY may improve survival outcomes for patients with relapsed/refractory hematologic malignancies, showing better overall survival and disease-free survival compared to single cord transplantation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Rohtesh S. Mehta, David Marin, Amin Alousi, Christopher G. Kanakry, Richard E. Champlin, Katayoun Rezvani, Elizabeth J. Shpall, Kristin Page, Shahinaz M. Gadalla, Daniel Weisdorf, Partow Kebriaei
Summary: In adult patients with acute lymphoblastic leukemia, younger haploidentical donors have better overall survival compared to older HLA-matched unrelated donors. Donor age is a prognostic factor for survival in hematopoietic cell transplantation.
Article
Hematology
Michael R. Grunwald, Mei-Jie Zhang, Hany Elmariah, Mariam H. Johnson, Andrew St Martin, Asad Bashey, Minoo Battiwalla, Christopher N. Bredeson, Edward Copelan, Corey S. Cutler, Biju R. George, Vikas Gupta, Christopher Kanakry, Rohtesh S. Mehta, Filippo Milano, Alberto Mussetti, Ryotaro Nakamura, Taiga Nishihori, Wael Saber, Melhem Solh, Daniel J. Weisdorf, Mary Eapen
Summary: This study compared outcomes of HLA-haploidentical relative and HLA-matched unrelated donor hematopoietic cell transplantation in patients with myelodysplastic syndrome. While the haploidentical relative group had higher relapse rates and lower disease-free survival rates, overall survival rates did not differ between donor types. This was due to lower rates of GVHD in haploidentical relative transplants, although mortality associated with chronic GVHD was higher in the unrelated donor group.
Article
Hematology
Mahasweta Gooptu, Rizwan Romee, Andrew St Martin, Mukta Arora, Monzr Al Malki, Joseph H. Antin, Christopher N. Bredeson, Claudio G. Brunstein, Saurabh Chhabra, Ephraim J. Fuchs, Nilanjan Ghosh, Michael R. Grunwald, Christopher G. Kanakry, Natasha Kekre, Jospeh P. McGuirk, Ian K. McNiece, Rohtesh S. Mehta, Marco Mielcarek, Fillipo Milano, Dipenkumar Modi, Ran Reshef, Scott R. Solomon, Mark A. Schroeder, Edmund K. Waller, Yoshiro Inamoto, Robert J. Soiffer, Mary Eapen
Summary: After comparing outcomes of 2036 haploidentical and 284 matched unrelated donor (MUD) transplantations with posttransplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis, it was found that MUD transplants had lower acute GVHD and nonrelapse mortality rates, as well as higher disease-free and overall survival, especially in recipients of reduced-intensity regimens. However, no significant differences were observed in patients receiving myeloablative conditioning regimens, highlighting the importance of donor-recipient HLA matching for allogeneic transplantation.
Article
Medicine, General & Internal
Yu-Qian Sun, Yu Wang, Feng-Rong Wang, Chen-Hua Yan, Yi-Fei Cheng, Yu-Hong Chen, Yuan-Yuan Zhang, Ting-Ting Han, Wei Han, Pan Suo, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
Summary: A prospective clinical trial using a reduced-intensity conditioning regimen with different haploidentical donors for second transplantation in patients with graft failure showed promising results in achieving neutrophil engraftment. Further investigation is needed to confirm the effectiveness of this salvage option.
FRONTIERS IN MEDICINE
(2021)
Article
Immunology
Guangyang Weng, Zhiping Fan, Huiwen Xue, Fen Huang, Na Xu, Hua Jin, Sijian Yu, Zhixin Ye, Jingchao Fan, Li Xuan, Qifa Liu
Summary: The study found that haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome (BOS) compared to HLA-matched sibling donor stem cell transplantation. Additionally, the use of antithymocyte globulin (ATG) and mixed grafts may be protective factors in reducing the incidence of BOS.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Emanuele Angelucci, Boris Afanasyev, Jan J. Cornelissen, Simona Sica, Ellen Meijer, Fabio Ciceri, Gwendolyn Van Gorkom, Nicolaus Kroger, Hans Martin, Pietro Pioltelli, Antonio Risitano, Jonathan Canaani, Bipin N. Savani, Jaime Sanz, Mohamad Mohty
Summary: In the setting of PTCy for patients with acute leukemia, haplo bone marrow transplantation resulted in a lower incidence of GvHD compared with UD mobilized peripheral blood stem cell transplantation. However, differences in GvHD did not affect overall survival outcomes, suggesting both donor sources are equally acceptable for allo-HCT.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Francesca Lorentino, Myriam Labopin, Fabio Ciceri, Luca Vago, Katharina Fleischhauer, Boris Afanasyev, Nicolaus Kroeger, Jan J. Cornelissen, Montserrat Lovira, Ellen Meijer, Antonin Vitek, Ahmet Elmaagacli, Didier Blaise, Annalisa Ruggeri, Christian Chabannon, Arnon Nagler, Mohamad Mohty
Summary: The study compared outcomes of acute leukemia patients receiving UD-HCT with PTCy prophylaxis and found no significant differences in major outcome indicators between those with 10/10 and 9/10 HLA allele matching.
Article
Cell Biology
Bu Yeon Heo, Myung-Won Lee, Suyoung Choi, Yunju Jung, Thi Thuy Duong Pham, Yunseon Jang, Jung-Hyun Park, Sora Kang, Jeong Suk Koh, Deog-Yeon Jo, Jaeyul Kwon, Ik-Chan Song
Summary: Autoimmune limbic encephalitis (LE) is a rare complication of allogeneic hematopoietic stem cell transplantation (HSCT). This retrospective study investigated LE in patients who underwent haploidentical HSCT and found that patients with LE had worse clinical outcomes and overall survival. Higher levels of systemic inflammatory markers in the early post-transplant period, as well as higher baseline interleukin-6 levels before HSCT, were associated with LE development. Impaired expansion of regulatory T cells was also observed in LE patients.
Article
Hematology
Anand Srinivasan, Enass Raffa, Donna A. Wall, Tal Schechter, Muhammad Ali, Yogi Chopra, Raymond Kung, Kuang-Yueh Chiang, Joerg Krueger
Summary: This study compared the outcomes of transplantation in pediatric patients with hematologic malignancies using different donor sources. It found that haplo PBSC HSCT with PTCy had comparable results to MSD and MUD BM HSCT in children, with a lower incidence of chronic GVHD.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Immunology
Fumiya Wada, Junya Kanda, Satoshi Yoshioka, Takayuki Ishikawa, Takashi Akasaka, Yasunori Ueda, Hirokazu Hirata, Yasuyuki Arai, Kazuhiro Yago, Naoyuki Anzai, Mitsumasa Watanabe, Takashi Ikeda, Akihito Yonezawa, Kazunori Imada, Mitsuru Itoh, Toshiyuki Kitano, Tomoharu Takeoka, Masakatsu Hishizawa, Masaharu Nohgawa, Nobuyoshi Arima, Kousuke Asagoe, Tadakazu Kondo, Akifumi Takaori-Kondo
Summary: Unrelated cord blood (UCB) and haploidentical related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) are alternative options for treating patients without a HLA-matched donor. This study compared the outcomes of UCB and PTCy-haplo transplantation in hematological malignancy patients and found that overall survival was comparable between the two groups. Neutrophil and platelet engraftment were delayed in the UCB group, but nonrelapse mortality risk and graft-versus-host disease incidence were similar between the groups. UCB transplantation showed a lower relapse rate in acute myeloid leukemia patients.
Article
Biophysics
Max J. Rieger, Sebastian M. Stolz, Antonia M. Mueller, Rahel Schwotzer, Gayathri Nair, Dominik Schneidawind, Markus G. Manz, Urs Schanz
Summary: Hematopoietic cell transplantation from haploidentical donors (haploHCT) has proven to be a feasible and effective treatment for AML and MDS. The overall survival and progression-free survival rates are similar to those of HLA-identical MRD and MUD transplants, but haploHCT is associated with higher non-relapse mortality due to fatal infections.
BONE MARROW TRANSPLANTATION
(2023)
Article
Medicine, General & Internal
Liping Dou, Lu Wang, Xin Li, Yvchen Liu, Fei Li, Lijun Wang, Xiaoning Gao, Wenrong Huang, Shuhong Wang, Chunji Gao, Li Yu, Daihong Liu
Summary: The study found that using ATG as part of GVHD prophylaxis in MSD-PBSCT patients can significantly reduce the incidence of chronic GVHD without increasing the risk of relapse and nonrelapse mortality.
Article
Biophysics
Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde-Dahl, Jan J. J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Peter Remenyi, Gerard Socie, Gwendolyn van Gorkom, Helene Labussiere-Wallet, Xiao-Jun Huang, Marie Therese Rubio, Jenny Byrne, Charles Craddock, Laimonas Griskevicius, Fabio Ciceri, Mohamad Mohty
Summary: This study compared the outcomes of hematopoietic stem cell transplants in acute myeloid leukemia patients in first complete remission from different donor sources. The results showed that acute graft-versus-host disease (GVHD) was more common in all non-sibling donor groups. Chronic GVHD rates were also higher in certain unrelated donor groups. However, overall survival and leukemia-free survival did not differ significantly between donor types.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Rohtesh S. Mehta, Rima M. Saliba, Sassine Ghanem, Amin M. Alousi, Gabriela Rondon, Paolo Anderlini, Gheath Al-Atrash, Qaiser Bashir, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Amanda Olson, Betul Oran, Uday R. Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Neeraj Saini, Samer A. Srour, Richard E. Champlin, Katayoun Rezvani, Elizabeth J. Shpall
Summary: Despite the use of post-transplantation cyclophosphamide (PTCy), haploidentical donor hematopoietic cell transplantation (HCT) still has inferior outcomes compared to HLA-matched donor HCT. The haploidentical group had higher nonrelapse mortality and poorer progression-free survival and overall survival compared to the matched unrelated donor group. Relapse was the most common cause of death in all groups. The haploidentical group also had higher risk of infections, hemorrhagic cystitis, cardiovascular toxicities, and slower reconstitution of certain immune cells.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Review
Hematology
Pongthep Vittayawacharin, Piyanuch Kongtim, Stefan O. Ciurea
Summary: Myelodysplastic syndromes (MDS) are a group of diverse hematopoietic stem cell tumors primarily affecting older individuals, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. In recent years, the use of reduce-intensity conditioning regimens and haploidentical donors for transplantation has improved treatment outcomes. However, treatment-related mortality remains a limitation, highlighting the importance of pre-transplant evaluation for older patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Fateeha Furqan, Kwang W. Ahn, Yue Chen, Manmeet Kaur, Syed A. Abutalib, Nausheen Ahmed, Sairah Ahmed, Mohamed A. Kharfan-Dabaja, Johnathan Friedberg, Tara Gregory, LaQuisa Hill, Cole Sterling, Stephan K. Barta, Mazyar Shadman, Miguel-Angel Perales, Jasmine Zain, Alex F. Herrera, Craig Sauter, Mehdi Hamadani
Summary: This study evaluated the outcomes of allo-HCT in patients with relapsed/refractory ALCL and found that it can result in durable disease control in a significant proportion of patients. However, refractory disease and racial minority status predicted inferior outcomes after allo-HCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Letter
Hematology
Benjamin J. J. Lee, Shawn P. P. Griffin, Jean Doh, Piyanuch Kongtim, Alexandre Chan, Susan O'Brien, Deepa Jeyakumar, Stefan O. O. Ciurea
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Review
Oncology
Diana Gulei, Rares Drula, Gabriel Ghiaur, Anca Dana Buzoianu, Yelena Kravtsova-Ivantsiv, Ciprian Tomuleasa, Aaron Ciechanover
Summary: The ubiquitin-proteasome system (UPS) is crucial for protein degradation, and its dysregulation is closely related to malignant pathologies. KPC1, an E3 ubiquitin ligase component, plays a key role in cancer by regulating p27 signaling and the NF-xB pathway. KPC1 maintains the ubiquitination of cytoplasmic p27, influencing cell-cycle progression, and also induces the ubiquitination of p105 to control NF-xB signaling. Therapeutic reinforcement of the KPC1-p50 axis shows promising tumor suppressor activity in multiple malignancies.
Article
Oncology
Sung-Eun Lee, Feng Wang, Maison Grefe, Abel Trujillo-Ocampo, Wilfredo Ruiz-Vasquez, Koichi Takahashi, Hussein A. Abbas, Pamella Borges, Dinler Amaral Antunes, Gheath Al-Atrash, Naval Daver, Jeffrey J. Molldrem, Andrew Futreal, Guillermo Garcia-Manero, Jin S. Im
Summary: The purpose of this study is to find immune-related biomarkers to predict effective antitumor immunity in myelodysplastic syndrome (MDS) during immunotherapy and/or hypomethylating agent treatment. Peripheral blood samples from 55 MDS patients were analyzed for immune subsets, T-cell receptor repertoire, gene mutations, and immune-related gene expression profiling. The results showed that clinical responders to immunotherapy exhibited expansion of central memory CD8+ T cells, diverse TCR repertoire, higher mutation burden, and favorable changes in immune landscape.
CLINICAL CANCER RESEARCH
(2023)
Article
Hematology
Benjamin J. Lee, Piyanuch Kongtim, Jean Doh, Shawn P. Griffin, Alexandre Chan, Susan O'Brien, Stefan O. Ciurea, Deepa Jeyakumar
Summary: The use of triple intrathecal (IT) chemotherapy during HyperCVAD is a feasible alternative to standard of care (SOC) CNS prophylaxis for the treatment of acute lymphoblastic leukemia (ALL). It does not result in differences in CNS relapse-free survival, cumulative incidence of relapse, or overall survival compared to SOC. However, it significantly reduces the number of IT doses administered and the need for additional outpatient appointments.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
David Hui, Sairah Ahmed, Nico Nortje, Marina George, Clark R. Andersen, Kaycee Wilson, Diana Urbauer, Christopher Flowers, Eduardo Bruera
Summary: Goals-of-care discussions can help patients understand their illness and communicate their treatment preferences. A study compared the impact of a goals-of-care program on ICU mortality between patients with hematologic malignancies and solid tumors. The program improved goals-of-care documentation for blood cancer patients but did not change ICU mortality, while solid tumor patients had less improvement in documentation but significantly lower ICU mortality.
Letter
Hematology
Faheem Farooq, Justin S. Brandt, Elyce Cardonick, Evgeniya Polushkina, Julie Vose, Sairah Ahmed, Praveen Ramakrishnan Geethakumari, Adam J. Olszewski, Hesham Yasin, Umar Farooq, Nada Hamad, Yong Lin, Charlotte Maggen, Robert Fruscio, Mina Mhallem Gziri, Karina Dahl Steffensen, Frederic Amant, Andrew M. Evens
Review
Immunology
Emaan Haque, Ibrahim N. Muhsen, Walid Rasheed, Riad El Fakih, Mahmoud Aljurf
Summary: This review examines parasitic infections in hematopoietic stem cell transplantation (HSCT) recipients, focusing on major infections affecting different organ systems. Understanding the epidemiology, risk factors, and clinical presentations of these infections is crucial for timely intervention and successful management.
TRANSPLANT INFECTIOUS DISEASE
(2023)
Article
Cell Biology
Ke Zeng, Meixian Huang, Mi-Ae Lyu, Joseph D. Khoury, Sairah Ahmed, Krina K. Patel, Boro Dropulic, Jane Reese-Koc, Paolo F. Caimi, Tara Sadeghi, Marcos de Lima, Christopher R. Flowers, Simrit Parmar
Summary: With the increasing accessibility and use of CAR T cell therapy, real-world toxicity remains a challenge. Allogeneic umbilical cord blood-derived regulatory T cells (Tregs) have shown promise in treating acute inflammatory syndromes. The addition of Tregs did not interfere with the anti-tumor activity of CAR T cells and helped mitigate the hyper-inflammatory state induced by CAR T cells.
Article
Hematology
Uday R. Popat, Oren Pasvolsky, Roland Bassett Jr, Rohtesh S. Mehta, Amanda Olson, Julianne Chen, Amin M. Alousi, Gheath Al-Atrash, Qaiser Bashir, Alison M. Gulbis, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Betul Oran, Neeraj Saini, Terri Lynn Shigle, Samer A. Srour, Jeremy L. Ramdial, Katayoun Rezvani, Muzaffar H. Qazilbash, Borje S. Andersson, Richard E. Champlin, Elizabeth J. Shpall
Summary: A fractionated myeloablative busulfan regimen was found to be effective in reducing nonrelapse mortality without increasing relapse rate for patients undergoing allogeneic hematopoietic cell transplantation, especially for older patients and those with comorbidities.
Article
Hematology
Hemant S. Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V. Michelis, Taiga Nishihori, Mrinal Patnaik, Muhammad Bilal Abid, Mahmoud Aljurf, Yasuyuki Arai, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Karen Ballen, Minoo Battiwalla, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie I. Brown, Rodrigo Martino, Jean-Yves Cahn, Paul Castillo, Jan Cerny, Saurabh Chhabra, Edward Copelan, Andrew Daly, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Cesar O. Freytes, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Omer Jamy, Jacinth Joseph, Christopher G. Kanakry, Nandita Khera, Maxwell M. Krem, Yachiyo Kuwatsuka, Hillard M. Lazarus, Lazaros J. Lekakis, Hongtao Liu, Dipenkumar Modi, Pashna N. Munshi, Alberto Mussetti, Neil Palmisiano, Sagar S. Patel, David A. Rizzieri, Sachiko Seo, Mithun Vinod Shah, Akshay Sharma, Melhm Sohl, Scott R. Solomon, Matthew Ulrickson, Celalettin Ustun, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Trent Wang, Baldeep Wirk, Amer Zeidan, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Daniel J. Weisdorf, Wael Saber, Mohamed A. Kharfan-Dabaja
Summary: This study analyzed the outcomes of allo-HCT in BPDCN patients and found that it provides durable remissions and long-term survival. Younger age and allo-HCT in CR1 were associated with improved survival, while the use of MAC-TBI reduced relapse risk and improved DFS. Further research and innovative strategies are needed to improve the outcomes of BPDCN.
Article
Biochemistry & Molecular Biology
Alexandru Leonard Alexa, Ancuta Jurj, Ciprian Tomuleasa, Adrian Bogdan Tigu, Raluca-Miorita Hategan, Daniela Ionescu
Summary: This study aimed to compare the effects of different anesthetic drugs on postoperative outcomes in colorectal cancer patients and investigate the potential role of intravenous lidocaine on colon cancer cell functions. The results showed that different anesthesia techniques did not significantly affect apoptosis, migration, and cell cycle of colorectal cancer cells. However, the propofol group showed significantly increased TP53 gene expression, while the lidocaine with sevoflurane group showed increased cell viability. Further studies are needed to explore the effects of propofol and lidocaine on different colon cancer cell lines and assess the clinical implications.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2023)
Review
Oncology
Raluca Munteanu, Ciprian Tomuleasa, Cristina-Adela Iuga, Diana Gulei, Tudor Eliade Ciuleanu, Triantafillos Liloglou
Summary: Understanding and applying epigenetic processes can revolutionize lung cancer care, improving treatment outcomes and quality of life. However, understanding the role of epigenetic drugs in treatment remains a challenge.
Article
Medicine, General & Internal
Melen Brinza, Andra Grigore, Mihaela Dragomir, Dumitru Jardan, Cerasela Jardan, Paul Balanescu, Claudia Cristina Tarniceriu, Oana Viola Badulescu, Cristina Blag, Ciprian Tomuleasa, Adina Traila, Margit Serban, Daniel Coriu, Rita Carlotta Santoro
Summary: This study investigated the inversions of intron 22 and intron 1 in Romanian patients with severe HA, and found that large intron inversions played a major causative role in severe HA. Additionally, intron 1 inversion was associated with inhibitor development.
MEDICINA-LITHUANIA
(2023)